Skip to main content

Table 2 Correlation of ID3 expression with clinic-pathologic characteristics in AML patients

From: Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation

Patient’s parameters

Total AML

CN-AML

Low (n=87)

High (n=86)

P

Low (n=50)

High (n=30)

P

Sex, male/female

44/43

49/37

.447

23/27

14/16

1.000

Median age, years (range)

57(18-82)

59 (21-88)

.727

57 (21-82)

59 (21-88)

.970

Median WBC, ×109/L (range)

37 (1.4-297.4)

5.5 (0.4-171.9)

.000

50.5 (1.4-297.4)

8.6 (0.6-115.4)

.000

Median PB blasts, % (range)

49 (0-98)

17 (0-97)

.001

49 (0-98)

18.5 (0-97)

.137

Median BM blasts, % (range)

77 (32-100)

65.5 (30-100)

.002

76.5 (32-100)

71 (30-100)

.161

FAB classifications

  

.162

  

.370

M0

6

10

.307

1

2

.553

M1

24

20

.601

14

10

.624

M2

19

19

1.000

14

6

.595

M3

5

11

.124

0

1

.375

M4

20

14

.339

11

5

.774

M5

12

6

.212

10

4

.552

M6

0

2

.246

0

0

-

M7

0

3

.121

0

1

.375

No data

1

1

1.000

0

1

.375

Karyotypes

  

.342

-

-

-

normal

50

30

.004

-

-

-

t(15;17)

5

10

.188

-

-

-

t(8;21)

3

4

.720

-

-

-

inv(16)

4

6

.535

-

-

-

+8

4

4

1.000

-

-

-

del(5)

0

1

.497

-

-

-

-7/del(7)

2

5

.278

-

-

-

11q23

1

2

.621

-

-

-

others

6

8

.590

-

-

-

complex

11

14

.524

-

-

-

No data

1

2

.621

-

-

-

Risks (cytogenetic)

  

.069

   

Good

12

20

.121

-

-

-

Intermediate

59

42

.014

-

-

-

Poor

15

22

.199

-

-

-

No data

1

2

.621

-

-

-

Risks (molecular)

  

.265

  

.061

Good

12

21

.084

0

1

.497

Intermediate

51

41

.172

45

29

.402

Poor

23

22

1.000

5

0

.151

No data

1

2

.621

0

0

-

Gene mutations

 FLT3a (+/-)

32/55

17/69

.018

22/28

9/21

.244

 NPM1 (+/-)

32/55

16/70

.011

29/21

14/16

.361

 DNMT3A (+/-)

24/63

18/68

.376

18/32

11/19

1.000

 IDH2 (+/-)

7/80

10/76

.456

5/45

5/25

.489

 IDH1 (+/-)

6/81

10/76

.307

3/47

6/24

.073

 TET2 (+/-)

8/79

7/79

1.000

5/45

4/26

.722

 RUNX1 (+/-)

4/83

5/81

.747

2/48

5/25

.096

 TP53 (+/-)

3/84

11/75

.028

0/50

1/29

.375

 NRAS (+/-)

5/82

7/79

.566

4/46

3/27

1.000

 CEBPAb (+/-)

10/77

3/83

.080

7/43

1/29

.247

 WT1 (+/-)

7/80

3/83

.329

4/46

2/28

1.000

 PTPN11 (+/-)

5/82

3/83

.720

4/46

1/29

.645

 KIT (+/-)

2/85

5/81

.278

0/50

0/30

-

 U2AF1 (+/-)

2/85

5/81

.278

1/49

0/30

1.000

 KRAS (+/-)

3/84

4/82

.720

2/48

1/29

1.000

 ASXL1 (+/-)

0/87

3/83

.121

0/50

1/29

.375

  1. Cytogenetic and molecular risk classifications are based on the 2017 European LeukemiaNet (ELN) classification. Patients without required information for FAB subtypes, karyotypes and molecular/cytogenetic risks are considered as no data
  2. AML Acute myeloid leukemia, WBC White blood cells, PB Peripheral blood, BM Bone marrow, FAB French-American-British classification
  3. a FLT3 mutation indicates both FLT3-ITD (high and low ratios) and FLT3-TKD mutations
  4. b CEBPA mutation indicates both mono- and bi-allelic CEBPA mutation